English
Drug resistant Enterobacterale are a major threat to global healthcare, and it has become clear in the last years that new tools are urgently needed to combat these bacteria. In the endeavour to develop new antibiotics against these Gram-negative bacteria, a major hurdle is the bacterial expression of efficient and promiscuous xenobiotic efflux pumps that limit the efficacy of known antibiotics and new chemical entities under development. Potent inhibitors of these efflux systems would be truly game-changers in breaking the xenobiotic defence system of these bacteria. Previously discovered efflux pump inhibitors (EPIs) have not yet reached clinical phases but have proven the druggability of these targets. We have recently discovered a novel class of efflux pump inhibitors able to boost the activity of a large panel of antibiotics in both Escherichia coli and Klebsiella pneumoniae Gram-negative bacteria. The EPI-4-AMR consortium will aim to further optimise this chemical series to identify more potent, specific and safe EPIs which will boost the antibiotic efficacy in drug sensitive and resistant clinical Enterobacterales strains and in relevant mouse infection models. This class of EPIs, in combination with efflux pump substrate antibiotics, will offer a new therapeutic alternative to treat multidrug-resistant infections by Enterobacterales.
